EUVIMEDEUVIMED entdecken
Crossref

Pembrolizumab-associated hepatobiliary disorders: a real-world pharmacovigilance study using the FDA Adverse Events Reporting System (FAERS)

Pembrolizumab-assoziierte hepatobiliäre Erkrankungen: Real-World-Pharmakovigilanzstudie mit dem FDA Adverse Events Reporting System (FAERS)

Likun Ding, Ning Ma, Meiyou Liu, Di Zhang, JuanLi Zhang, Tingting Fan, Jingwen Wang

Drug Research · 01.10.2025 · 75 (08) · 320-325

DOI: 10.1055/a-2662-9565 ↗

Auf einen Blick

FAERS-Daten zeigten einen Zusammenhang zwischen Pembrolizumab und hepatobiliären unerwünschten Ereignissen. Die meisten traten innerhalb von drei Monaten nach Therapiebeginn auf.

Fragestellung

Welche hepatobiliären unerwünschten Ereignisse sind in FAERS mit Pembrolizumab assoziiert?

Methode

Pharmakovigilanzstudie mit FAERS-Daten von Q1/2009 bis Q3/2024; Signal-Detektion mit Reporting Odds Ratio (ROR); Signifikanz bei unterer 95 %-CI-Grenze >1 und ≥5 Ereignissen.

Ergebnisse

20.225.379 unerwünschte Ereignisse in FAERS, davon 45.774 mit Pembrolizumab als „primary suspected“ Drug. 101 Signale auf PT-Ebene, 56 als signifikant. Medianer TTO: 63 Tage.

Schlussfolgerung der Autor:innen

Auf Basis der FAERS-Pharmakovigilanzdaten sollten unterschiedliche hepatobiliäre unerwünschte Ereignisse unter Pembrolizumab eng überwacht und entsprechend der Indikation behandelt werden.

Kernaussagen

  • Pembrolizumab war mit hepatobiliären unerwünschten Ereignissen assoziiert.
  • 101 Signale auf PT-Ebene, 56 davon signifikant.
  • Die meisten Ereignisse traten innerhalb von drei Monaten auf.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Drug Research, erschienen am 01.10.2025. Verfasst von Likun Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adverse Drug Reaction Reporting Systems, Antineoplastic Agents, Immunological, Chemical and Drug Induced Liver Injury. Die Arbeit nennt 15 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to evaluate hepatobiliary disorders adverse events associated with pembrolizumab by using the Food and Drug Administration Adverse Event Reporting System (FAERS). We collected FAERS data from the first quarter of 2009 to the third quarter of 2024 and used reporting odds ratio (ROR) to detect pembrolizumab-associated hepatobiliary adverse events (AEs). A signal was considered significant when the lower limit of the 95% confidence interval (CI) of the ROR exceeded 1, and≥5 AEs were reported. Serious and nonserious cases were compared by statistical analysis, and signals were further prioritized using a rating scale. A total of 20,225,379 AEs were reported in the FAERS database, of which 45,774 AEs listed pembrolizumab as the ‘primary suspected’ drug. Pembrolizumab treatment was significantly associated with hepatobiliary disorders. Among these AEs, 101 signals were detected at the preferred term (PT) levels, and 56 of them were identified as significant signals by using disproportionality analyses. The median time-to-onset (TTO) was 63 days. Notably, most hepatobiliary AEs occurred within three months after pembrolizumab therapy. Based on pharmacovigilance data from FAERS, different hepatobiliary AEs should be closely monitored and managed according to the indications for which pembrolizumab is used.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAdverse Drug Reaction Reporting SystemsAntineoplastic Agents, ImmunologicalChemical and Drug Induced Liver InjuryBiliary Tract DiseasesHumansPharmacovigilanceUnited StatesUnited States Food and Drug AdministrationMaleFemaleMiddle AgedAgedAdultDatabases, FactualAged, 80 and over

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.

Zitieren

APA

Ding, L., Ma, N., Liu, M., Zhang, D., Zhang, J., Fan, T., & Wang, J. (2025). Pembrolizumab-associated hepatobiliary disorders: a real-world pharmacovigilance study using the FDA Adverse Events Reporting System (FAERS). Drug Research, 75(08), 320-325. https://doi.org/10.1055/a-2662-9565

Vancouver

Ding L, Ma N, Liu M, Zhang D, Zhang J, Fan T, et al. Pembrolizumab-associated hepatobiliary disorders: a real-world pharmacovigilance study using the FDA Adverse Events Reporting System (FAERS). Drug Research. 2025;75(08):320-325. doi:10.1055/a-2662-9565

BibTeX
@article{Ding2025,
  author = {Ding, Likun and Ma, Ning and Liu, Meiyou and Zhang, Di and Zhang, JuanLi and Fan, Tingting and Wang, Jingwen},
  title = {Pembrolizumab-associated hepatobiliary disorders: a real-world pharmacovigilance study using the FDA Adverse Events Reporting System (FAERS)},
  journal = {Drug Research},
  year = {2025},
  volume = {75},
  number = {08},
  pages = {320--325},
  doi = {10.1055/a-2662-9565}
}
Kostenlos starten →